AbCellera and MassBiologics Partner to Discover Fully Human Antibodies Against Drug-Resistant Bacteria
20.7.2016 15:00 | NASDAQ OMX
VANCOUVER, British Columbia, 2016-07-20 15:00 CEST (GLOBE NEWSWIRE) --
AbCellera Biologics Inc., a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, today announced its third antibody discovery collaboration with MassBiologics of the University of Massachusetts Medical School.
This new collaboration, funded by the Defense Advanced Research Project Agency (DARPA) under the ADEPT-PROTECT program, focuses on addressing the rapidly-growing, unmet global health threat caused by the multidrug resistant bacteria,Klebsiella pneumoniae. This pathogen is among the leading causes of hospital-acquired (nosocomial) infections worldwide, and has emerged as a major concern for patients. AbCellera will apply its single-cell antibody discovery platform to identify panels of antibody candidates against Klebsiella pneumoniae directly from human volunteers.
“AbCellera’s technology has the throughput, speed and capacity to deeply screen natural human antibody responses to these pathogens,” said Carl Hansen, CEO and co-founder of AbCellera. “We are pleased at the opportunity to expand our collaboration with MassBiologics, and believe this work will further demonstrate the strength of our approach for rapid human antibody discovery, immune profiling, and vaccine development.”
This partnership builds on the successes of two earlier DARPA-funded collaborations between AbCellera and MassBiologics, from which novel antibodies for potential therapeutics to enterotoxigenic E. coli and Ebola virus were discovered.
About AbCellera Biologics Inc.
AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.
AbCellera’s lead technology is a proprietary single cell antibody discovery platform that provides pharma and biotech partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans. For more information, please visit www.abcellera.com
MassBiologics of the University of Massachusetts Medical School is the only publicly owned, non-profit FDA-licensed manufacturer of vaccines and other biologic products in the United States. The laboratory was established in 1894 by the state Board of Health to produce diphtheria antitoxin. Since that time, the focus at MassBiologics has been to improve public health through applied research, development and production of biologic products. In 1997, the Commonwealth of Massachusetts transferred MassBiologics operations from the Department of Public Health to UMass Medical School to “maintain their public purpose, preserving their ability to compete in an increasingly competitive marketplace and to maximize their value to the Commonwealth.”
About the University of Massachusetts Medical School
The University of Massachusetts Medical School has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $270 million in research funding annually, 80 percent of which comes from federal funding sources. The mission of the Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery with its clinical partner, UMass Memorial Health Care. For more information, visithttp://www.umassmed.edu/.
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
PayByPhone Appoints Francis Dupuis as new CEO24.8.2017 01:14 | Pressemelding
VANCOUVER, British Columbia, Aug. 23, 2017 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it has appointed Francis Dupuis as President and Chief Executive Officer effective August 23rd, 2017. Kush Parikh, former President and CEO, has stepped down from the role after his successful 3.5-year term with the business. During his time at PayByPhone, Kush led the business to profitability, established a strong focus on end customers and was pivotal in its ground-breaking sale to Volkswagen Financial Services. "With more than 20 years of experience in the software industry and a deep product background, Francis is exactly the kind of leader we need to further grow and innovate in the parking market on an international scale," said Stefan Imme, Head of M&A and Investment Management at Volkswagen Financial Services AG. Francis, a long-standing member of the executive team at PayByPhone, takes the reins at a
EPAM Hosts Scratch Conference in Budapest to Bring Together IT Educators Around the World23.8.2017 16:00 | Pressemelding
NEWTOWN, Pa., Aug. 23, 2017 (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, will host the Scratch Conference in Budapest, Hungary from August 24-25, 2017. The event is one of six conferences held globally to bring together hundreds of Scratch educators and IT experts. Developed by MIT, Scratch is a foundational tool and coding platform used primarily by children to learn the basics of programming. During this free event, attendees will hear from over 60 experts and explore all facets of computing, including best practices in using Scratch and additional tools that integrate with the platform. Several renowned speakers will attend the conference including Mitchel Resnick, Professor of Learning Research at the MIT Media Lab and Chair of the Scratch Foundation; Ariam Mogos, Learning Lead, Office of Innovation at UNICEF; and Genevieve Smith-Nunes, Entrepreneur and a Lecturer at Roeha
Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine23.8.2017 13:00 | Pressemelding
Novel vaccine candidate, NanoFlu(TM), outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study GAITHERSBURG, Md., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced that data from a preclinical study of its nanoparticle influenza vaccine candidate with its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) have been published in the journal Vaccine. Novavax is developing NanoFlu to protect older adults from seasonal influenza. The manuscript describes the formulation of Novavax' novel seasonal influenza vaccine candidate, NanoFlu, based on the 2017-2018 World Health Organization (WHO) recommended influenza strains. The study, conducted in ferrets, found that NanoFlu induced hemagglutination-inhibition (HAI) and microneutralizing (MN) antibodies against a broad range of influenza subtypes. In a head-to-head comparison against standard-dose and high-do
Crown Bioscience Names Dr. Leon Hall Vice President of Global Scientific Excellence23.8.2017 12:29 | Pressemelding
SANTA CLARA, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today the appointment of Dr. Leon Hall as Vice President of Global Scientific Excellence. In his new role, Dr. Hall will be responsible for overseeing global R&D programs and advancing Crown Bioscience's scientific excellence initiatives. "Leon's appointment reinforces Crown Bioscience's dedication to innovation and commitment to providing the highest quality therapeutic technology services," said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. "His extensive scientific and operational experience will serve Crown Bioscience well as we expand to meet the growing needs of preclinical research to the global
Blackbird Energy Inc. annonserer utnevnelsen av Allan Dixon som sjef for bedriftsutvikling23.8.2017 12:02 | Pressemelding
CALGARY, Alberta, 23. aug. 2017 (GLOBE NEWSWIRE) - Blackbird Energy Inc. (TSX-V:BBI) («Blackbird») har gleden av å kunngjøre utnevnelsen av Allan Dixon som sjef for bedriftsutvikling. I denne rollen vil Dixon være ansvarlig for investorrelasjoner, kommunikasjonsinitiativer og strategiske bedriftsbevissthetsprogrammer i Nord-Amerika og Europa. Dixon har en omfattende bakgrunn i Calgarys olje- og gassindustri med erfaring fra investorrelasjoner ved Birchcliff Energy Ltd., aksjeanalyse ved National Bank Financial og investeringsrelatert bankvirksomhet ved Tristone Capital. Dixon har en bachelorgrad i handelsfag med spesialisering innen finans fra Dalhousie University. «Jeg er veldig glad for å ønske Allan velkommen til Blackbird-teamet, og jeg ser frem til å jobbe med ham. Med sin varierte bakgrunn og erfaring med å jobbe med noen av verdens fremste innovatører i bransjen, har jeg den største tillit til at han vil være et verdifullt tilskudd til teamet vårt og en ressurs fo
International Body Positive Mentor, Arabella S. Ruby, Launches New Fashion Collection Under the Xehar Brand, Arabella by Xehar23.8.2017 12:00 | Pressemelding
Xehar's successful ambassador marketing campaign continues to drive online sales while spreading body positive messages among millennials around the world PLAYA VISTA, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Today Xehar launches their newest collection Arabella by Xehar, an edgy and contemporary plus size fashion line targeting progressive millennials. High demand for Xehar's custom clothing lines can be seen by the recent collection Laura by Xehar, which sold out in a record 10 days. Xehar has developed a proven method in creating collections inspired by Body Positive Mentors who have a significant social media following. A photo is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/10d6e5d8-c740-4c41-aa56-2255e6f70ad9 "Customers appreciate authenticity, and we are seeing great results by sharing our products through our Body Positive Mentors," says Hadari Oshri, CEO and founder of Xehar. "We are actively searching for m
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom